Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women

Breast Cancer Research and Treatment

Volumn 96, Issue 2, 2006, Pages 197-202

  Lee, Kyoung Mu ^a,b   Park, Sue Kyung ^c   Hamajima, Nobuyuki ^d   Tajima, Kazuo ^e   Choi, Ji Yeob ^a   Noh, Dong Young ^b   Ahn, Sei Hyun ^f   Yoo, Keun Young ^a   Hirvonen, Ari ^g   Kang, Daehee ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Konkuk University   (South Korea)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f University of Ulsan College of Medicine   (South Korea)

^g FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

Breast cancer; Genetic polymorphism; IL 1B; IL 1RN

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HISTOLOGY; HUMAN; INTERVIEW; KOREA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; TEACHING HOSPITAL;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KOREA; MENOPAUSE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33645227422     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9079-6     Document Type: Article

References (28)

1. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, Turkel G, Polverini PJ, Goldberg ID, Rosen EM: Expression of interleukin-1beta in human breast carcinoma. Cancer 80(3): 421-434, 1997
2. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, Lindquist RR, Barrows G, Kreutzer DL: Cytokines in human breast cancer: IL-1 alpha and IL-1 beta expression. Oncol Rep 6(1): 65-70, 1999
3. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 18(4): 293-302, 2000
4. Witkin SS, Gerber S, Ledger WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34: 204-209, 2002
5. Coussens LM, Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002
6. El-Omar EM, Carrington M, Cho WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776): 398-402, 2000
7. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simoes M: Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 121(4): 823-829, 2001
8. Sehouli J, Mustea A, Konsgen D, Katsares I, Lichtenegger W: Polymorphism of IL-1 receptor antagonist gene: role in cancer. Anticancer Res. 22(6A): 3421-3424, 2002
9. Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Inoue M, Hirose K, Tajima K: Significant reduction in breast cancer risk for Japanese women with interleukin 1B -31 CT/TT relative to CC genotype. Jpn J Clin Oncol 32(10): 398-402, 2002
10. Smith KC, Bateman AC, Fussell HM, Howell WM: Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31(4): 167-173, 2004
11. Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson RN, Toossi Z: Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 189(12): 1863-1874, 1999
12. Dabrowski MP, Stankiewicz W, Plusa T, Chcialowski A, Szmigielski S: Competition of IL-1 and IL-1ra determines lymphocyte response to delayed stimulation with PHA. Mediators Inflamm 10(3): 101-107, 2001
13. Danis VA, Millington M, Hyland VJ, Grennan D: Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99(2): 303-310, 1995
14. Bioque G, Crusius JB, Koutroubakisn I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS: Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 102(2): 379-383, 1995
15. Santtila S, Savinainen K, Hurme M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47(3): 195-198, 1998
16. Hamajima N, Matsuo K, Saito T, Tajima K, Okuma K, Yamao K, Tominaga S: Interleukin 1 polymorphisms, lifestyle factors, and Helicocacler pylori infection. Jap J Cancer Res 92: 383-389, 2001
17. Park SK, Yoo KY, Lee SJ, Kim SU, Ahn SH, Noh DY, Choe KJ, Strickland PT, Hirvonen A, Kang D: Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 10(4): 301-309, 2000
18. Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, Noh DY, Ahn SH, Hirvonen A, Kang D: Genetic polymorphisms of TGF-β1 & TNF-β and breast cancer risk. Br Cancer Res Treat 90(2): 149-55, 2005
19. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desain SB, Atkin SL: Evidence for transcriptional activation of ER alpha by IL-1beta in breast cancer cells. Int J Oncol 15(6): 1251-1254, 1999
20. Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, Okai T: The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 49(3): 371-377, 2002
21. Reichlin S, Chen G, Nicolson M: Blood to brain transfer of leptin in normal and interleukin-1 beta-treated male rats. Endocrinology 141(6): 1951-1954, 2000
22. Hu X, Juneja SC, Maihle NJ, Cleary MP: Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94(22): 1704-1711, 2002
23. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X: Molecular mechanisms in the growth stimulation of breast cancer cells by leptin. Cancer Res 64: 5870-5875, 2004
24. Rose DP, Komninou D, Stephenson GD: Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5(3): 153-165, 2004
25. Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, Kollinger M, Scholmerich J, Gross V: Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut 41(5): 651-657, 1997
26. Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI, Cominelli F: Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 117(4): 806-813, 1999
27. DeMichele A, Martin AM, Mick R, Gor P, Wary L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B: Interleukin-6-174G → C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63: 8051-8056, 2003
28. Lacopetta B, Grieu F, Joseph D: The -174G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 90: 419-422, 2004